Overcoming oxaliplatin resistance and toxicity in colorectal cancer: the emerging role of lipid-based nanocarriers
Journal of Pharmacy and Pharmacology · 04.11.2026 · 78 (11)
DOI: 10.1093/jpp/rgag135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 10.11.2026. Verfasst von Abhishek Chauhan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Oxaliplatin, Lipids. Die Arbeit nennt 145 Literaturangaben.
Abstract (Originalsprache)
Objectives
To provide a comprehensive overview of lipid-based nanocarriers for oxaliplatin (OXA) delivery in colorectal cancer (CRC), with emphasis on their potential to improve pharmacokinetics, enhance tumour accumulation, enable controlled drug release, and overcome OXA resistance.
Methods
Relevant literature on OXA, CRC, lipid-based nanocarriers, drug resistance, tumor targeting, co-delivery, and stimuli-responsive delivery systems was reviewed. The review focused on liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid micelles, and advanced lipid-based systems, including passive and active targeting strategies and approaches for overcoming therapeutic resistance. Key findings Lipid-based nanocarriers demonstrated potential to improve OXA delivery through enhanced tumour accumulation, controlled release, prolonged drug exposure, and improved intracellular uptake. Active targeting using folate, CD44, peptides, or antibodies, along with co-delivery, tumor microenvironment modulation, and externally triggered release, may further enhance therapeutic efficacy and help overcome multidrug resistance. However, most evidence remains preclinical, and challenges including formulation stability, tumor heterogeneity, large-scale manufacturing, and regulatory requirements limit clinical translation.
Conclusions
Lipid-based nanocarriers represent a promising strategy for improving OXA therapy in CRC, particularly for addressing toxicity, drug resistance, and inefficient tumor delivery. Nevertheless, the limited clinical evidence for OXA-loaded lipid nanocarriers necessitates further pharmacokinetic, toxicological, manufacturing, and well-designed clinical studies before their clinical effectiveness can be established.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
ORCID-Profile: Abhishek Chauhan, Ankit Awasthi
Zitieren
APA
Chauhan, A., Kumar, M., & Awasthi, A. (2026). Overcoming oxaliplatin resistance and toxicity in colorectal cancer: the emerging role of lipid-based nanocarriers. Journal of Pharmacy and Pharmacology, 78(11). https://doi.org/10.1093/jpp/rgag135
Vancouver
Chauhan A, Kumar M, Awasthi A. Overcoming oxaliplatin resistance and toxicity in colorectal cancer: the emerging role of lipid-based nanocarriers. Journal of Pharmacy and Pharmacology. 2026;78(11). doi:10.1093/jpp/rgag135
BibTeX
@article{Chauhan2026,
author = {Chauhan, Abhishek and Kumar, Mohit and Awasthi, Ankit},
title = {Overcoming oxaliplatin resistance and toxicity in colorectal cancer: the emerging role of lipid-based nanocarriers},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {11},
doi = {10.1093/jpp/rgag135}
}
EUVIMED